Open AccessEvaluation of a Multidrug Chemotherapy Protocol (ACOPA II) in Dogs With Lymphoma
Author(s) -
III Nathaniel C. Myers,
Moore Antony S.,
Rand William M.,
Gliatto John,
Cotter Susan M.
Publication year - 1997
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.1997.tb00476.x
Subject(s) - medicine , prednisone , vincristine , cyclophosphamide , lymphoma , chemotherapy , canine lymphoma , gastroenterology , surgery , lymphoblastic lymphoma , complete remission , immunology , immune system , t cell
A chemotherapeutic protocol using cyclophosphamide, vincristine, prednisone, doxorubicin, and L‐asparaginase (ACOPA II) was evaluated in dogs with lymphoma. The response rate for 68 dogs treated with ACOPA II (complete remission [CR] 65%, partial remission [PR] 10%) was lower than that for 41 dogs treated with a related protocol previously evaluated (ACOPA I; CR 76%, PR 12%). Initial treatment with doxorubicin and prednisone did not decrease the prevalence or severity of toxicity during induction. The mortality during induction was 22%. The median duration of CR for dogs treated with ACOPA II was 9 months, with 40% still in remission at 1 year and 21% at 2 years. The rate of CR was lower for dogs with signs of illness at presentation (substage b ) and for dogs weighing less than 15 kg. Age was negatively correlated with survival time and duration of remission. Dogs with immunoblastic lymphoma had a more favorable prognosis than did those with lymphoblastic lymphoma. Survival times were also longer for dogs in substage a at presentation. Seven dogs in which treatment was discontinued while in remission had comparable remission duration to that achieved by dogs receiving long‐term maintenance chemotherapy.